Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Xuanzhu Biopharma-B (02575.HK) Presents Phase III Clinical Data of DiLuoAke at AACR
Recommend 2 Positive 2 Negative 3 |
||||
|
||||
|
Xuanzhu Biopharma-B (02575.HK) announced that the Group presented, in an oral session at the 2026 American Association for Cancer Research (AACR) Annual Meeting, the results of its Phase III clinical study of DiLuoAke as a first-line treatment for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The data demonstrated that DiLuoAke showed statistically significant and clinically meaningful efficacy advantages in the first-line treatment of ALK-positive advanced NSCLC. DiLuoAke tablets (brand name: Xuan Fei Ning? are a next-generation oral ALK inhibitor independently developed by the Group, specifically designed for the treatment of ALK-rearranged advanced non-small cell lung cancer. (de/d) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
